About Xstrahl

Adrian holds a physics degree and MS from Imperial College London and started his career in a technical sales role for a major optical components company. In 2003, he was recruited by a radiotherapy company to manage a non-contact patient monitoring system and he commercialized a 3D ultrasound technology from Cambridge University. He joined Xstrahl in 2006 as sales director, leading the sales and marketing for our orthovoltage x-ray therapy systems. In 2009, he helped commercialize SARRP from Johns Hopkins University and moved to the US in 2011 to continue to expand the research division of Xstrahl. Adrian has served as global CEO since 2018 following a management buyout.

Amanda qualified and practiced as a clinical radiographer at St Thomas’ Hospital, specializing in radiotherapy for NMSC following her MSc. She left the clinical world to join Xstrahl in 2000, initially as a clinical sales specialist. During her career at Xstrahl, she has supervised marketing, product management, business development, and regulatory affairs, leading up to current position as Chief Science Officer. Amanda was instrumental in the commercialization of SARRP and in developing Xstrahl’s European installed base. She is actively engaged in several grant projects and working with our clinical and research partners to develop peer-reviewed publications.

Vineet has more than 25 years of experience in the medical device industry with a career that includes leadership roles in prominent technology companies. At Xstrahl, Vineet is leading the transformation of the product landscape in both the Life Sciences and Medical Divisions. Before joining Xstrahl in 2021, he served as the Director of R&D at Best Nomos (a division of Best Medical International). Vineet has also held leadership roles in GE Healthcare, Tata Elxsi Limited and Rosses Medical Systems. He is a senior member of IEEE and is the author or co-author of several publications in peer reviewed journals. Vineet graduated with a M.S. & Ph.D. in Biomedical Engineering from the University of Akron, Ohio.

Dr. Shaffer joined Xstrahl in 2020 as medical director. He received his BSc in biomedical science from Manchester University and his MBBS from the University College of London Medical School. He formally served as chair of the radiotherapy strategy group in one of the NHS divisions. Dr. Shaffer has deep expertise in radiotherapy development and innovation. He currently serves as the UK lead for skin cancer and benign radiotherapy for GenesisCare UK. Clinically, he has used radiation therapy and chemotherapy to treat a range of cancers.

Paul joined Xstrahl in 2018 following the management buyout. He is a highly experienced CFO, with a background in a variety of companies in both private equity and public markets, including roles at Tottenham Hotspur Plc, Giraffe Concepts, and The Brighton Pier Group Plc. He has played an instrumental role in shaping the finance team and reporting landscape at Xstrahl, and provides strategic assistance across the organization on matters ranging from operations to human resources. Paul is a Chartered Accountant and holds a bachelors degree in accounting and finance from University of Leeds.